Arecor Therapeutics Announces Transition in Business Strategy
Arecor Therapeutics plc (AIM: LON: AREC), a prominent biopharmaceutical firm, has outlined significant changes with plans to cease operations at its subsidiary, Tetris Pharma, by 2025. This decision aligns with a collaborative agreement with Xeris BioPharma Holdings, Inc. to return commercial rights of the glucagon auto-injector pen, Ogluo®, intended for managing severe hypoglycemia.
Strategic Review Highlights Financial Challenges
The need for restructuring stemmed from a thorough strategic review. This review unveiled troubling financial dynamics at Tetris Pharma, primarily influenced by soaring supply chain costs and rigid pricing strategies that have adversely affected profit margins. An unfortunate loss of a key NHS tender by a partner further worsened revenue forecasts for 2025, impacting sales outside of the Ogluo® product line. As a result, Arecor will fully impair goodwill and intangibles linked to Tetris Pharma, projecting a loss of around £3 million in 2024.
Enhancing R&D Focus on Insulin
As part of this restructuring, Arecor intends to concentrate its efforts on high-value research and development initiatives, particularly on its state-of-the-art ultra-rapid acting insulin candidate, AT278. The firm is eagerly exploring co-development partnerships for AT278, aiming to accelerate its market introduction.
Advancements in Peptide Delivery
In addition to advancing AT278, Arecor is also pioneering oral peptide delivery systems. With encouraging preliminary data from non-clinical pharmacokinetic studies for a GLP-1 receptor agonist formulation, these critical studies are projected to commence in the first half of 2025, revealing Arecor’s commitment to innovation in diabetes management.
Leadership Insights on Enhanced Capabilities
Sarah Howell, CEO of Arecor, expressed that this pivot in strategy passionately reflects the company's resolve to utilize its Arestat™ technology in fields with substantial transformative potential. Howell emphasizes that Arecor will continue to advance its portfolio of Arestat™ enabled therapeutics, employing a technology licensing model poised to drive future revenues.
Understanding the Implications of Tetris Pharma's Closure
The ongoing license and supply agreement with Xeris provides Tetris Pharma with category rights to commercialize Ogluo® across the EEA, UK, and Switzerland. However, as discussions unfold regarding the dissolution of this partnership, Arecor aims to work alongside regulators and patient advocacy groups to navigate this transition smoothly. Notably, alternative glucagon products remain accessible in all targeted markets, ensuring that patients maintain their treatment options.
Looking Ahead: Arecor's Future Directions
The strategic decision to refocus its operations solidifies Arecor's intent to prioritize cutting-edge advancements in diabetes treatment and technology solutions that can offer significant health benefits. As the company shifts its attention, stakeholders can anticipate a concentrated effort from Arecor in redefining treatment paradigms and enhancing patient care through innovative therapeutic approaches.
Frequently Asked Questions
What led Arecor to shut down Tetris Pharma?
The decision stems from financial struggles faced by Tetris Pharma, compounded by increased costs and loss of key tenders affecting revenue.
What is Arecor focused on after this strategic pivot?
Arecor is concentrating on high-value research initiatives, particularly ultra-rapid acting insulin candidate AT278 and oral peptide delivery systems.
How will the closure of Tetris Pharma affect its products?
While Tetris Pharma will cease operations, alternative glucagon products will remain available in all territories previously serviced.
What is the status of the agreement with Xeris BioPharma?
Arecor is currently discussing the termination of its partnership with Xeris regarding commercial rights to Ogluo®.
What innovations is Arecor pursuing in diabetes care?
Arecor is advancing its ultra-rapid acting insulin AT278 and conducting studies on an oral GLP-1 receptor agonist to improve diabetes treatment options.
